Any pharmaceutical or biotech company seeking a medicinal product marketing authorisation in the European Union (EU) now faces the need to implement the requirements of the European Medicines Agency (EMA) Guideline on Computerised Systems and Electronic Data in Clinical Trials. Effective on 9 September 2023, the guideline introduces a framework of standards for computerised systems and electronic data in clinical trials and drives the imminent need to assess whether those standards are complied with upon the effective date.
The purpose at a glance
To ensure the integrity, reliability and regulatory compliance of computer systems in clinical trials, the EMA has established a guideline that governs their use and addresses the complexity of these computerised systems. The guideline consolidates expectations on the use of computerised systems, the collection and use of electronic data, and provides a framework to be upheld by sponsors, investigators and their service providers.
Who is impacted by the new EMA guidelines?
In alignment with the ICH GCP, the responsibility for the proper use of computerised systems and management of electronic data in clinical research is assigned to two key stakeholders:
- Investigators and their institutions, laboratories and other technical departments or clinics
- Sponsors that directly or via service providers supply, store and/or manage and operate computerised systems (software and hardware) and the records generated by them.
Understanding vs underestimating the scope
The discussion within the wider industry about the scope of the guideline and its impacts has directed us to seek a clarification on the definition of ‘clinical data’. The EMA confirmed to ICON that “the scope of the guideline should not be considered to be restricted to systems handling data of trial participants, and we would encourage a more global reading and interpretation”. Thus, the scope of this guideline broadly extends across computerised system and electronic data use and management in clinical trials. Therefore, an assumption that the scope is limited to clinical data generated at investigative sites is an underestimation of the scope.
Building confidence in EMA compliance
One of the key aspects the guideline addresses is the validation of computerised systems. It outlines the requirements for establishing the reliability and accuracy of these systems, ensuring that they consistently perform their intended functions. By maintaining a comprehensive documentation of system specifications, testing protocols and maintenance procedures, and by implementing thorough validation processes, sponsors should achieve the confidence in the integrity of the data generated by these systems and compliance to the standards expected by the EMA.
With paramount importance of data integrity and security in clinical research, it comes with no surprise that the EMA guideline places a great emphasis on the need for appropriate access controls, user authentication and data encryption to protect against unauthorised access and data breaches. The guideline also stresses the importance of audit trails, ensuring transparency and traceability of data modifications.
Considerations for the EMA guidelines beyond technology
When thinking about computerised systems and electronic data, some but not all may be tempted to arrive at a conclusion that the guideline pertains purely to technical, information technology (IT) related aspects. However, we encourage you to think about it through the lenses of several key perspectives:
- Processes: Do your standard operating procedures (SOPs) and other controlled documents embed and comply to the requirements of this guideline? Do they allow and guide the relevant process roles to make appropriate assessment on the systems and electronic data or guide them on relevant procedures to be used for electronic data access and use?
- People: Do you have any people in impacted roles who need to have a specific level of awareness of this guideline, its requirements, and the extent to which it impacts their roles? What level of training and change management is needed?
- Clinical trial project delivery: How does the guideline impact your delivery in ongoing or new clinical trials? What considerations should apply to be in compliance for any investigational product targeting a marketing authorisation in EU?
- Vendors: Do your vendors comply with the requirements of this guideline and how that compliance is ensured and overseen?
- Budgets and other financial implications: Does the adherence to this guideline impact costs on clinical research projects or require investments by the company in technology and system updates, process updates, people training?
- Investigators: How do we qualify investigators ensuring appropriate electronic system suitability, access and use? How do we define source data agreements and access to source data and EMR source data at investigative sites?
These are some key considerations where each clinical research related function within complex, matrix-based organisations – whether a sponsor, CRO or vendor – need to assess their daily interface with systems and electronic data. The guideline encourages all impacted stakeholders to think about clinical data as both “data derived from a trial participant and any other trial related data handled in e-systems for the purposes of conducting and reporting a clinical trial, and relevant for the clinical trial”, as explained by EMA in the clarification letter to ICON.
Preparing to comply with new EMA guidelines
The clinical research industry has had line of sight on the guideline and its implications since the first draft was released in September 2021. Some have been working across their organisational functions to assess the impacts and ensure effective and timely implementation of this guideline. Achieving readiness with an adequate assessment and mitigation of the ultimate impacts of this guidance will be a significant undertaking given the complexity and multilayer nature of clinical research. ICON recommends clients, investigators and other stakeholders conduct assessments of their clinical trial computerised systems and electronic data use, access and management, and advocates for raising the awareness of this new guideline globally.
Compliance of computerised systems and electronic data to the regulatory standards is critical for clinical trial data reliability and protection of patient safety and rights. As the new EMA guidance compliance date approaches, everyone in the industry should be readying to comply.
Contact us to learn how we can help you navigate the challenges of meeting the new regulations and prepare your business for success.
Authored by:
Vesta Marciulioniene, Director Global Regulatory Clinical Services, ICON Biotech
Jo Hulbert, Executive Director Global Regulatory Clinical Services, ICON Biotech
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel